Real‐world treatment outcomes of neovascular Age‐related Macular Degeneration in the Netherlands
Abstract Purpose To compare treatment outcomes of treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD) with bevacizumab as the first‐line treatment, according to the guidelines of the Dutch Ophthalmological Society, with those treated first with either ranibizumab or aflibercept, as used in many other countries, all treated using a treat‐and‐extend strategy. Methods Data were obtained from the prospectively designed Fight Retinal Blindness! outcomes registry. The primary outcome was the mean change from baseline in visual acuity of all treated eyes, after 12, 24 and 36... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2020 |
Reihe/Periodikum: | Acta Ophthalmologica ; volume 99, issue 6 ; ISSN 1755-375X 1755-3768 |
Verlag/Hrsg.: |
Wiley
|
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-28808574 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://dx.doi.org/10.1111/aos.14712 |